Theraclone signs merger deal with PharmAthene

U.S. biotech firms PharmAthene and Theraclone Sciences entered into a merger agreement to form a new company that specializes in cancer drugs and vaccines for infectious diseases. The combined firm, which will be headed by Theraclone CEO Cliff Stocks, will use PharmAthene's name and will be based in Seattle.

View Full Article in:

Seattle Times, The · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health